innovaTV205 with Ignace Vergote

IJGC Podcast

BMJ Group에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 BMJ Group 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

3M ago 26:25

MP3•에피소드 홈

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Em. Ignace Vergote to discuss innovaTV205. Prof. Vergote was Chairman of the Department of Gynaecology and Obstetrics at the Catholic University Leuven from 2003-2020. He published more than 1050 papers on gynecologic cancer in peer-reviewed journals, and his work was cited more than 90,000 times. He served as President of IGCS, ESGO, EORTC-GCG and ENGOT.

Highlights:

Tissue factor is almost always highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate.
TV combined with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated recurrent/metastatic cervical cancer.
The results show that the combination of TV with current treatments may improve outcomes and provide novel treatment options for patients with first or later recurrences and/or primary metastatic cervical cancer.

356 에피소드

#Medicine #BMJ Group #Fitness #Pedro Ramirez